Dechra Pharmaceuticals Announces Acquisition of Invetx Inc. to Expand Portfolio in Veterinary Pharmaceuticals
Jul 18, 2024•over 1 year ago
Acquiring Company
Dechra
Acquired Company
Invetx, Inc.
Cheshire
BostonPharmaceuticalBiotechnologyBiotechnologyDescription
Invetx Inc., a pioneer in protein-based therapeutics for animal health, has agreed to be acquired by Dechra Pharmaceuticals Limited for up to $520 million. This acquisition will complement Dechra’s broad portfolio of specialty therapeutics for companion animals and accelerate its differentiated position in the veterinary health industry. Invetx’s pipeline of monoclonal antibody therapeutics and species-specific, half-life extension platform will further enhance Dechra’s expertise in core therapeutic areas.
M&A Insights
Based on deal dataIntegration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed